GAMMA Investing LLC Has $36,000 Position in The Chemours Company $CC

GAMMA Investing LLC increased its position in The Chemours Company (NYSE:CC) by 130.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,175 shares of the specialty chemicals company’s stock after buying an additional 1,799 shares during the quarter. GAMMA Investing LLC’s holdings in Chemours were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC acquired a new position in shares of Chemours in the first quarter valued at approximately $27,000. UMB Bank n.a. increased its position in Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 948 shares during the period. Farther Finance Advisors LLC increased its position in Chemours by 170.7% during the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 1,444 shares during the period. SouthState Corp acquired a new stake in Chemours during the 1st quarter valued at approximately $34,000. Finally, Parallel Advisors LLC increased its position in Chemours by 132.6% during the 2nd quarter. Parallel Advisors LLC now owns 5,634 shares of the specialty chemicals company’s stock valued at $65,000 after purchasing an additional 3,212 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Price Performance

Shares of CC opened at $16.12 on Monday. The Chemours Company has a 12-month low of $9.13 and a 12-month high of $22.38. The business’s fifty day moving average is $14.98 and its 200 day moving average is $12.98. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16. The stock has a market cap of $2.41 billion, a P/E ratio of -5.76 and a beta of 1.65.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The company had revenue of $1.62 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period last year, the business earned $0.38 EPS. Chemours’s quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 15th were paid a dividend of $0.0875 per share. The ex-dividend date was Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.2%. Chemours’s dividend payout ratio (DPR) is -12.50%.

Insiders Place Their Bets

In related news, CEO Denise Dignam acquired 4,068 shares of the company’s stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the purchase, the chief executive officer owned 191,546 shares in the company, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CC shares. Truist Financial increased their target price on shares of Chemours from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Mizuho increased their target price on shares of Chemours from $16.00 to $19.00 and gave the company an “outperform” rating in a research report on Tuesday, September 23rd. Royal Bank Of Canada increased their target price on shares of Chemours from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, July 3rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research report on Saturday, September 27th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Chemours currently has an average rating of “Hold” and a consensus price target of $17.63.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.